176 related articles for article (PubMed ID: 33341902)
1. Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer.
Imano N; Murakami Y; Kubo K; Kawahara D; Takeuchi Y; Nishibuchi I; Kimura T; Kochi M; Takakura Y; Shimizu W; Egi H; Uegami S; Ohge H; Takahashi S; Ohdan H; Nagata Y
J Radiat Res; 2021 Mar; 62(2):300-308. PubMed ID: 33341902
[TBL] [Abstract][Full Text] [Related]
2. S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.
Su M; Zhu LC; Wei HP; Luo WH; Lin RF; Zou CL
PLoS One; 2014; 9(9):e106162. PubMed ID: 25181318
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
[TBL] [Abstract][Full Text] [Related]
5. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
8. [A Case Report of a Pathological Complete Response of Rectal Cancer to Preoperative Chemoradiotherapy with Tegafur].
Morikawa T; Teraishi F; Shima Y; Iwata J
Gan To Kagaku Ryoho; 2016 Mar; 43(3):381-4. PubMed ID: 27067861
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Kamijo A; Murayama C; Akiba T; Nakayama Y
Oncology; 2011; 81(5-6):306-11. PubMed ID: 22156392
[TBL] [Abstract][Full Text] [Related]
10. [Preoperative chemoradiotherapy with S-1 for advanced low rectal cancer].
Kitani K; Okajima K; Sato K; Isono S; Kimura H; Ikeda M; Inoue K; Iwama M; Tsujie M; Nakayama T; Fujiwara Y; Murata M; Yukawa M; Ota Y; Inoue M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2122-4. PubMed ID: 22202303
[TBL] [Abstract][Full Text] [Related]
11. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
[TBL] [Abstract][Full Text] [Related]
14. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
16. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
17. A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer.
Chen CF; Huang MY; Huang CJ; Wu CH; Yeh YS; Tsai HL; Ma CJ; Lu CY; Chang SJ; Chen MJ; Wang JY
Int J Colorectal Dis; 2012 Jun; 27(6):727-36. PubMed ID: 22258885
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
